Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

• Published in: Annals of the rheumatic diseases Vol. 80; no. 10; pp. 1339 - 1344
• Main Authors: Haberman, Rebecca H, Herati, Ramin, Simon, David, Samanovic, Marie, Blank, Rebecca B, Tuen, Michael, Koralov, Sergei B, Atreya, Raja, Tascilar, Koray, Allen, Joseph R, Castillo, Rochelle, Cornelius, Amber R, Rackoff, Paula, Solomon, Gary, Adhikari, Samrachana, Azar, Natalie, Rosenthal, Pamela, Izmirly, Peter, Samuels, Jonathan, Golden, Brian, Reddy, Soumya M, Neurath, Markus F, Abramson, Steven B, Schett, Georg, Mulligan, Mark J, Scher, Jose U
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and European League Against Rheumatism 01.10.2021; Elsevier Limited; BMJ Publishing Group
• Subjects: Antibodies; arthritis; CD8 antigen; Cell activation; Coronaviruses; COVID-19; COVID-19 vaccines; Disease; Epidemiology; Flow cytometry; Immune response (cell-mediated); Immune response (humoral); Immunocompetence; Immunogenicity; Immunoglobulin G; Immunomodulation; Infections; Inflammatory diseases; Influenza; Lymphocytes T; Methotrexate; mRNA; mRNA vaccines; Patients; Proteins; Psoriasis; psoriatic; rheumatoid; Rheumatoid arthritis; Severe acute respiratory syndrome coronavirus 2; Software; Spike protein; Steroids; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; vaccination; Vaccine efficacy; Vaccines; New York; United States > US; Germany; New York City New York; methotrexate; psoriatic; Covid-19; arthritis; rheumatoid; vaccination

ObjectiveTo investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment.MethodsEstablished patients at New York University Langone Health with IMID (n=51) receiving the BNT...